Research also indicated that panobinostat, another HDAC inhibitor, enhances trastuzumab’s efficacy by triggering a CXCR3-mediated NK cell and IFNγ-dependent immune response in breast cancer [120]. This evidence concerns the gene HDAC9 and breast carcinoma.